atezolizumab plus bevacizumab (n=336) vs. sorafenib (n=165)
randomized controlled trial
atezolizumab-bevacizumab
atezolizumab–bevacizumab group received 1200 mg of atezolizumab plus 15 mg per kilogram of body weight of bevacizumab intravenously every 3 weeks
sorafenib
400 mg of sorafenib orally twice daily
Dose modifications were not permitted in the atezolizumab–bevacizumab group but were allowed in the sorafenib group.
mHCC - 1st line (L1)
open design
111 sites in 17 countries
P3/two sided One analysis of PFS, two interim analyses, and a final analysis of OS. Repartition, reallocation and hierarchy OS PFS and ORR (arm A then arm B)
In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progressionÂfree survival outcomes than sorafenib
COSMIC-312, 2023 NCT03755791
atezolizumab plus cabozantinib (n=432) vs. sorafenib (n=217)
randomized controlled trial
cabozantinib plus atezolizumab
cabozantinib (orally) at 40 mg once daily, and atezolizumab intravenously at 1200 mg every 3 weeks
sorafenib
sorafenib 400 mg twice daily
mHCC - 1st line (L1)
open label
178 centres in 32 countries
P3 / PFS (cabozantinib plus atezolizumab vs sorafenib in ITT pop) and OS (c a vs s) in ITT pop / PFS (cabozantinib alone vs sorafenib in ITT pop)